Report Overview

The global analgesic infusion pumps market was pegged at US$ 2.96 billion in 2021 and is expected to witness a CAGR of 5.8% during the forecast period.

Market Fundamentals

The patients can self-administer the narcotic painkillers due to the analgesic infusion pumps. The doctor specifies the upper and lower limits for self-administration. The terminally ill, postoperative, and trauma patients frequently get analgesic infusion pumps. The analgesic infusion pumps administer fluids, drugs, and nutrients intravenously to the patient's circulatory systems. For infusion pumps, this route of delivery is frequently utilised. The analgesic infusion pumps' primary function is to reduce patients' pain. These patients typically have undergone surgery and are in excruciating pain.

[43686348]

Market Dynamics

The increasing need for analgesic drug treatments to relieve pain in chronic illnesses is expected to drive growth in the market for analgesic infusion pumps globally. Examples of chronic diseases include failed back syndrome, complicated pain syndrome, myocardial infarction, and post-operative pain. Additionally, analgesic infusion pumps are frequently utilised to treat neurological conditions like cerebral palsy and spinal cord damage. The global market for analgesic infusion pumps is expected to rise as a result of the low cost of these devices and rising consumer awareness.

Market Ecosystem

 The global analgesic infusion pumps market has been analyzed from four perspectives by product, application, end user and region.

Analgesic Infusion Pumps Market by Product

 Based on product, the global analgesic infusion pumps market has been segmented into patient-controlled analgesia pump and intrathecal pump. The patient-controlled analgesia pump product segment is leading the market due to their various benefits, including self-administration of doses.

Analgesic Infusion Pumps Market by Application

[6757658]

Based on application, the global analgesic infusion pumps have been segmented into post-surgical application, pain management accidents and trauma, labor pain, cancer patients, and others. Over the course of the forecast period, the pain management segment is expected to have a larger revenue share in the global analgesic infusion pump market. Hospitals and medical facilities are increasingly in need of Patient-Controlled Analgesia (PCA) pumps to alleviate post-operative pain.

Analgesic Infusion Pumps Market by End User       

Based on end user, the global analgesic infusion pumps have been segmented into hospitals, clinics, and others Due to the large patient pool, hospitals are the largest consumers of analgesic infusion pumps. But the home care segment is also growing at a significant rate owing to initiatives taken by the government to reduce the load on hospitals.

Analgesic Infusion Pumps Market by Region

Based on region, the global analgesic infusion pumps have been segmented into North America, Europe, Asia Pacific, and Rest of the World. During the projection period, it is anticipated that the market for analgesic infusion pumps in North America would grow. The analgesic infusion pumps market in North America is anticipated to grow as a result of a well-established healthcare infrastructure, the availability of reimbursement policies, rising patient acceptance of technologically improved treatment instruments, and considerable healthcare spending.

However, the market for analgesic infusion pumps in Asia-Pacific has expanded at the fastest rate in recent years and is predicted to develop even quicker in the years to come. The Asia-Pacific analgesic infusion pumps market is being driven by factors including expanding government initiatives, particularly in populous nations like China and India, expansion in the field of contemporary healthcare infrastructure, along with increased awareness regarding the use of infusion pumps.

Competitive Landscape

Some of the prominent players in the global analgesic infusion pumps market include 

• Baxter International Inc.
• Medtronic Inc.
• KD Scientific Inc.
• Animas Corporation
• Codman & Shurtleff Inc. 
• Braun Melsungen AG 
• Smith’s Medical, 
• Flowonix Medical Inc.
• Stryker Corp.
• Sorenson Medical Products Inc
• I-Flow Corp. 
• Hospira Inc. 
• Terumo Corporation.

Many companies are putting an emphasis on organic growth initiatives, including new launches, product approvals, and others like patents and events. Acquisitions and partnerships & collaborations were two examples of inorganic growth tactics in the market. These actions have enabled it possible for market players to grow their consumer bases and operations. With the growing demand for analgesic infusion pumps in the global market, it is projected that market players from this industry will benefit from lucrative growth prospects in the future.

Strategic development

• In January 2022, Smiths Medical was successfully acquired by CU Medical Inc. from Smiths Group plc., establishing a new infusion powerhouse. With pro forma combined revenues of around USD 2.5 billion, it is anticipated that this will improve revenue for both companies.
• In January 2020, the SynchroMed II intrathecal drug delivery device is now networked with Efficio by Medtronic, Ireland. It will enable doctors to administer customised drug delivery systems for patients with severe spasticity, cancer pain, and chronic pain more effectively.
• In August 2020, the Epic smart infusion pump was developed by Ivenix, Inc. to help reduce patient injuries associated to infusions. Ivenix is motivated by this validation to improve infusion delivery operations, clinical quality, and patient outcomes.
• In April 2021, the first and only infusion set in the world that may be used for up to seven days has been made accessible in a few European nations by Medtronic. This is in charge of transferring insulin from the pump into the human body. All MiniMed600 and 700 series insulin pumps are compatible with this new accessory kit.

Frequently Asked Questions About This Report